You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

56 Results
Guidelines and Advice
Status: Current
ID: GL-C50-17
Jan 2015
Guidelines and Advice
Status: Current
ID: GL-C50-18
Jan 2015
Guidelines and Advice
Status: Current
ID: GL-C50-21
Jul 2015
Guidelines and Advice
Status: Current
ID: GL-C50-20
May 2015
Drug
Other Name(s): Provera® (multiple brands available)
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2015
Drug
Other Name(s): Erbitux®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Aug 2023
Drug
Other Name(s): Caprelsa®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Aug 2023
Drug
Other Name(s): Zelboraf ®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Aug 2023
Drug
Other Name(s): Kadcyla®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Aug 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Panitumumab - Metastatic Colorectal Small Bowel or Appendiceal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PANitumumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    vemURAFenib - Monotherapy in patients with BRAF V600 mutation-positive unresectable stage Ill or stage IV melanoma, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
vemURAFenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
regorafenib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023

Pages